COMPANY PROFILE

AccurEdit Therapeutics

Explore full profile

ChinaFounded 2021Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2021
Headquarters: China
Employees: 12
Open positions: 1
Dealroom signal: 54.5/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Aug 2025	$75M	$300M	China Medical System Holdings · Tibet Rhodiola Pharmaceutical	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

AccurEdit Therapeutics website traffic

Latest recorded traffic for AccurEdit Therapeutics is 3.3K monthly website visits, up 3200% over the last three months. AccurEdit Therapeutics's team grew 9.1% over the past year.

Latest monthly visits3.3K 3-month web change+3200% 1-year team growth+9.1%

Monthly website visitsApr 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

/Suzhou, Jiangsu, China · Other · Jun 19, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PBProxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation	New York City, United States	Operational	77	$80M	$320M
RBReThink64 BionetworksIntercellular router system for large-molecule drug delivery	Fremont, United States	Operational
XBXanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing	Lower Merion Township, United States	Operational
CPCPTxAt CPTx, new treatment paradigms are developed to address unmet medical challenges, with an initial focus on infectious diseases	Planegg, Germany	Operational
TBTippingPoint BiosciencesTherapeutics company focused on drug discovery targeting the aberrant DNA in cancer cells	San Francisco, United States	Operational
LTLoQus23 TherapeuticsSmall molecule inhibitors for neurodegenerative genetic diseases	Cambridge, United Kingdom	Operational
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational
CTCeleris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases	Graz, Austria	Operational